Business
Gareth Morgan Named President of Qpex Biopharma, Inc.
SAN DIEGO, October 15, 2025--Qpex Biopharma, Inc., a Shionogi Group Company (hereafter "Qpex"), announced that Gareth Morgan, MS, MBA, most recently Senior Vice President and Global Head of Portfolio Management and AMR Policy at Shionogi Inc., has been appointed President of Qpex. Morgan succeeds Michael Dudley, Pharm.D., who has retired and stepped down from his role as President and CEO. Dr. Dudley will continue to serve as a strategic advisor to Qpex and Shionogi.
About this update from Shionogi & Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/3c4a6c6550a6c5f91db015a59b7c91cd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yU_lca2E0RanZ3RuBC99.g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3c4a6c6550a6c5f91db015a59b7c91cd","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Curr4qSmDZxMe8iPxSMFyw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/3c4a6c6550a6c5f91db015a59b7c91cd","width":1024,"height":512}},"lazy":false},{"type":"text","content":"SAN DIEGO, October 15, 2025--(BUSINESS WIRE)--Qpex Biopharma, Inc., a Shionogi Group Company (hereafter "Qpex"), announced that Gareth Morgan, MS, MBA, most recently Senior Vice President and Global Head of Portfolio Management and AMR Policy at Shionogi Inc., has been appointed President of Qpex. Morgan succeeds Michael Dudley, Pharm.D., who has retired and stepped down from his role as President and CEO. Dr. Dudley will continue to serve as a strategic advisor to Qpex and Shionogi.","length":498,"tagName":"p"},{"type":"text","content":"Shionogi Inc., a U.S.-based subsidiary of Shionogi & Co., Ltd., acquired Qpex in 2023. The acquisition brought Qpex’s expertise in antibiotic R&D along with its novel, internally discovered pipeline, including an investigational beta-lactamase inhibitor, to Shionogi, expanding the company’s anti-infective pipeline and further augmenting its R&D capabilities and expertise.","length":386,"tagName":"p"},{"type":"text","content":""I am honored to have led Qpex from its founding to becoming a Shionogi Group Company. Together we have expanded U.S.-based antibiotic R&D and are becoming true global leaders in anti-infective innovation," said Dr. Dudley. "I have had the opportunity to work closely with Gareth and am confident that his deep expertise in anti-infectives and tenure within Shionogi have prepared him to lead the teams advancing our pipeline programs. Additionally, his ability to establish strategic alliances, particularly with governments and global organizations, will be critical to bringing Qpex to the next level.""...